Access links:
CONTENT
Destacados
-
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Negredo, E., Garrabou, G., Puig, J., Lopez, S., Moren, C., Bellido, R., Ayen, R., Cardellach, F., Miro, O., and Clotet, B.Antivir Ther 13, 231-240.
-
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD.Clin Infect Dis 46, 1101-10.
-
Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999.
Mocroft, A., Horban, A., Clotet, B., d'Arminio Monforte, A., Bogner, J. R., Aldins, P., Staub, T., Antunes, F., Katlama, C., and Lundgren, J. D.HIV Med 9, 41-46.
-
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.N. Engl J Med 359. 1442-55.
-
Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.
Negredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet B.Antivir Ther. 2008;13(2):231-40.
